The latest price target for ADMA Biologics (NASDAQ:ADMA) was reported by Cantor Fitzgerald on March 4, 2025. The analyst firm set a price target for $25.00 expecting ADMA to rise to within 12 months (a possible 24.07% upside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for ADMA Biologics (NASDAQ:ADMA) was provided by Cantor Fitzgerald, and ADMA Biologics reiterated their overweight rating.

There is no last upgrade for ADMA Biologics

There is no last downgrade for ADMA Biologics.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ADMA Biologics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ADMA Biologics was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.

While ratings are subjective and will change, the latest ADMA Biologics (ADMA) rating was a reiterated with a price target of $25.00 to $25.00. The current price ADMA Biologics (ADMA) is trading at is $20.15, which is out of the analyst’s predicted range.